Lucioni Carlo, Finelli Carlo, Mazzi Silvio, Oliva Esther N
Springer Healthcare Italia S.r.l. Milano.
Am J Blood Res. 2013 Aug 19;3(3):246-59. eCollection 2013.
Myelodysplastic syndromes (MDS) encompass a range of myeloid neoplasms characterised by a defect in haematopoietic stem cell maturation, resulting in peripheral cytopenias. As a major consequence, most MDS patients become anaemic, so as to require red blood cell transfusions. To investigate the costs and the impact on quality of life (QOL) of MDS-separately in transfusion-independent (TI) and -dependent (TD) patients-a literature search was conducted. From Medline and Embase, 742 studies were identified, of which 17 were considered eligible. Total medical costs per patient/year range from $ 9,840 to $ 19,811 for the TI condition and from $ 29,608 to $ 51,066 in the TD condition, more than doubling when moving from the former condition to the latter. With regard to QOL, in the transition from TI to TD, QOL could be reduced by half depending on the studies. The TD condition negatively impacts on costs and the QOL of patients with MDS. Therapeutic strategies that reduce transfusion dependence may lead to broad benefits for patients and the community.
骨髓增生异常综合征（MDS）包括一系列髓系肿瘤，其特征是造血干细胞成熟存在缺陷，导致外周血细胞减少。主要后果是，大多数MDS患者会出现贫血，从而需要输注红细胞。为了分别调查非输血依赖（TI）和输血依赖（TD）的MDS患者的费用以及对生活质量（QOL）的影响，我们进行了文献检索。从Medline和Embase数据库中，我们识别出742项研究，其中17项被认为符合要求。TI状态下每位患者每年的总医疗费用为9840美元至19811美元，TD状态下为29608美元至51066美元，从前一种状态转变为后一种状态时费用增加了一倍多。关于生活质量，从TI转变为TD时，根据不同研究，生活质量可能会降低一半。TD状态对MDS患者的费用和生活质量有负面影响。降低输血依赖的治疗策略可能会给患者和社会带来广泛益处。
